AI-generated summary
The authors report a retrospective case series of 91 patients with dry eye caused by meibomian gland dysfunction who received intense-pulsed-light therapy with gland expression at one outpatient clinic. Physician-judged improvement in tear breakup time was found in 68 of 78 patients with data, and 93% reported satisfaction. The authors describe the results as preliminary and note that a larger controlled trial is underway.
- Participants
- 91
- Who or what was studied
- Patients with severe dry eye syndrome caused by meibomian gland dysfunction treated at a single outpatient clinic over 30 months
- Limits stated in the abstract
- The study was retrospective and noncomparative, with no control group, a single clinic, and tear breakup time data available for only 78 of 91 patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Objective
The purpose of this study was to determine the clinical benefits of intense-pulsed-light therapy for the treatment of dry-eye disease caused by meibomian gland dysfunction (MGD).
Background Data
MGD is the leading cause of evaporative dry eye disease. It is currently treated with a range of methods that have been shown to be only somewhat effective, leading to the need for advanced treatment options.
Methods
A retrospective noncomparative interventional case series was conducted with 91 patients presenting with severe dry eye syndrome. Treatment included intense-pulsed-light therapy and gland expression at a single outpatient clinic over a 30-month study. Pre/post tear breakup time data were available for a subset of 78 patients. For all patients, a specially developed technique for the treatment of dry eye syndrome was applied as a series of monthly treatments until there was adequate improvement in dry eye syndrome symptoms by physician judgment, or until patient discontinuation.
Results
Primary outcomes included change in tear breakup time, self-reported patient satisfaction, and adverse events. Physician-judged improvement in dry eye tear breakup time was found for 68 of 78 patients (87%) with seven treatment visits and four maintenance visits on average (medians), and 93% of patients reported post-treatment satisfaction with degree of dry eye syndrome symptoms. Adverse events, most typically redness or swelling, were found for 13% of patients. No serious adverse events were found.
Conclusions
Although preliminary, study results of intense-pulsed-light therapy treatment for dry eye syndrome caused by meibomian gland dysfunction are promising. A multisite clinical trial with a larger sample, treatment comparison groups, and randomized controlled trials is currently underway.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Dry eye. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.